A BETTER WAY

A Better Way to treat infertility is possible. We’re building one.

About Us

We are a medical device development and manufacturing company. We have created a device to enable affordable and accessible infertility treatment, as part of our mission to help democratize treatment globally. We are launching soon.

OUR Team

Daniel Wilson
Chief Executive Officer
Dr. Marion Vollmer
Chief Technology Officer
Patrick Welsh
Chief Revenue Officer

OUR ADVISORY Council

200 Years of Experience in the Healthcare Industry.

Diann Dalton Potestio

35 years Healthcare Experience
25 Product Launches

Iris Tam, PharmD

35 years Healthcare Experience
L
eading HEOR Specialist

Marc Scharen

40 years Healthcare Experience

Michael Petro

30 years Healthcare Experience

Warner Quon, PharmD

20 years Experience as a Pharmacist

COPE Calculator

Advertised “success rates” for fertility treatment typically don’t factor in cost. So we have invented a new metric for the industry: COst per PErcentage (COPE). This is your success and not the clinics, because the COPE factors in your costs, and tells you what you pay for every 1% chance of achieving a live birth.

CONTACT

Scroll to Top

Daniel Wilson

Chief Executive Officer / Co-founder

Daniel Wilson is a Co-founder of my123Baby Medical Limited. He currently serves as the CEO and Director/Secretary on the Board. He has 35 years of entrepreneurial experience running his own companies and helping make several startups successful. He created all of the documentation for Visual Banker at Footprint Software in Toronto which was purchased by IBM as its worldwide banking solution. He also helped Silicon Valley-based Seeker Software create the first Enterprise HR system on the Web, which eventually led to a multi-million-dollar sale of the company.

Before transitioning to Boost Fertility full time, he ran a successful native-English software training and documentation company (Training & Doc Guru) together with Dr. Marion Vollmer, establishing it as one of the top firms in the field and attracting some of Germany’s top companies as clients, including Zalando, GetYourGuide and ProSieben.

Dr. Marion Vollmer

Chief Technology Officer / Inventor / Co-founder

Dr. Marion Vollmer (PhD) is a Co-founder of my123Baby Medical Limited, CTO and a Director on the Board. Marion has interdisciplinary knowledge in biology, chemistry, and physics. Marion studied life sciences, focusing on molecular biology, human genetics, and immunology. During her PhD thesis at the Helmholtz Center Munich, she specialized in embryology and stem cell research and received her PhD in 2010 from the Technical University in Munich.

She moved on to work at the Faculty of Physics at the Ludwig Maximilian University in Munich where she worked with several applications of nanotechnology to study cellular processes, such as intra-cellular transport and cell movement. After that, at the Mechanical and Industrial Engineering Department at the University of Toronto, she became an expert in microfluidics for medical solutions and was a member of the inventor team of a microfluidic device for sperm preparation for assisted reproduction.

After leaving Toronto, Marion developed a medical device for sperm preparation that was specifically designed for commercialization and home usage. Our Pleiades Device is the centerpiece of the Boost Fertility solution.

Patrick Welsh

Chief Revenue Officer / Board Member

Patrick has had a distinguished career as a proven sales professional, consistently exceeding revenue goals by using a value-focused sales methodology, built on a foundation of superior relationship building and excellent communication skills. Most recently, he served as VP Sales at Deacom Inc and helped to scale the company for an exit while managing a sales team of 18 people.

Patrick also spent five years at Author-it Software where he was hired by the Board/CEO to develop an American go-to-market strategy to penetrate the Life Sciences vertical, culminating in the largest deal in the company’s 15 year history within six months, and eventually signing up most of the Top 10 pharma companies as clients, including Johnson & Johnson, Amgen, AstraZeneca, Roche, Abbvie, Novartis, Merck and Bristol-Myers Squibb.